{"gene":"SOCS1","run_date":"2026-06-10T07:46:37","timeline":{"discoveries":[{"year":1999,"finding":"SOCS1/JAB binds specifically to the phosphorylated tyrosine residue Y1007 in the activation loop of JAK2, requiring both the SH2 domain and an N-terminal extended SH2 subdomain (containing Ile68 and Leu75). An additional kinase inhibitory region (KIR) contributes to high-affinity binding to the JAK2 kinase domain and is required for inhibition of JAK2 signaling and kinase activity.","method":"In vitro binding assays, site-directed mutagenesis, kinase activity assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis defining binding residues and kinase inhibition mechanism; foundational mechanistic paper","pmids":["10064597"],"is_preprint":false},{"year":2018,"finding":"Crystal/structural studies revealed that the SOCS1 kinase inhibitory region (KIR) targets the substrate-binding groove of JAK with high specificity to block phosphorylation. SOCS1 has a compromised ability to recruit Cullin5 due to alterations within its SOCS box domain, making direct JAK catalytic inhibition its primary mode of action. SOCS1 does not bind the IFNγ receptor, distinguishing its mechanism from SOCS3.","method":"Structural determination (crystallography/biophysical), in vitro kinase assays, mutagenesis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural determination combined with functional validation and mutagenesis in a single rigorous study","pmids":["29674694"],"is_preprint":false},{"year":1998,"finding":"Three distinct domains of SOCS1/SSI-1 are required for suppression of IL-6 signaling: (1) the pre-SH2 domain (24 aa N-terminal to the SH2 domain), (2) the SH2 domain (required for association with JAK family kinases including JAK1, JAK2, TYK2), and (3) the SC-motif (SOCS box), which protects SOCS1 from proteasomal degradation. Deletion of the SH2 domain abolished co-association with TYK2.","method":"Deletion mutagenesis, co-expression/co-immunoprecipitation, reporter assays, proteasome inhibitor treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple domain deletion mutants tested with orthogonal assays (reporter, co-IP, proteasome inhibition) in one study","pmids":["9789053"],"is_preprint":false},{"year":2002,"finding":"SOCS1 and SOCS3 bind both recombinant and endogenous IRS1 and IRS2, promote their ubiquitination and subsequent proteasomal degradation. Mutations in the conserved SOCS box of SOCS1 abrogated interaction with the elongin BC ubiquitin-ligase complex without affecting IRS1/IRS2 binding, and abolished ubiquitination and degradation. Adenoviral expression of SOCS1 in mouse liver dramatically reduced hepatic IRS1 and IRS2 protein levels and caused glucose intolerance.","method":"Co-immunoprecipitation, ubiquitination assays, SOCS box mutagenesis, adenoviral gene delivery in mice, glucose tolerance testing","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (co-IP, ubiquitination assay, mutagenesis, in vivo mouse model) in one study","pmids":["12228220"],"is_preprint":false},{"year":2001,"finding":"The SOCS box of SOCS1 interacts with Cullin-2 (in addition to Elongin B/C) and promotes ubiquitination of the leukemic fusion protein TEL-JAK2, leading to its proteasomal degradation. Dominant-negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Degradation required JAK2 phosphorylation and high-affinity binding through the KIR and SH2 domain of SOCS1.","method":"Co-immunoprecipitation, ubiquitination assays, dominant-negative Cullin-2 overexpression, proteasome inhibitor experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstitution of ubiquitin ligase activity with multiple orthogonal approaches including dominant-negative rescue","pmids":["11278610"],"is_preprint":false},{"year":1998,"finding":"JAB/SOCS1 is strongly induced by IFN-γ; forced expression of JAB confers resistance to IFN-β and IFN-γ by inhibiting JAK1 and JAK2 activation and blocking STAT1 tyrosine phosphorylation and DNA-binding activity. IFN-resistant tumor cell clones expressed high constitutive levels of JAB.","method":"Stable cell line overexpression, antiviral assay, kinase activity assay, STAT1 phosphorylation and DNA-binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple functional assays (kinase, STAT phosphorylation, antiviral) in stable cell lines; independently corroborated by other papers","pmids":["9716595"],"is_preprint":false},{"year":2002,"finding":"SOCS1 expression is rapidly induced in macrophages by LPS. SOCS1 deficiency increases sensitivity to LPS-induced shock and augments inflammatory cytokine production. Forced SOCS1 expression inhibits LPS-induced NF-κB and STAT1 activation. SOCS1-deficient mice fail to develop LPS tolerance.","method":"SOCS1 knockout mice, macrophage stimulation assays, NF-κB and STAT1 reporter/phosphorylation assays, forced SOCS1 expression","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated independently in two concurrent papers (PMID 12433373 and 12433365) using KO mice and overexpression with consistent findings","pmids":["12433373","12433365"],"is_preprint":false},{"year":2009,"finding":"SOCS1 is required for p53 transcriptional activity, DNA binding, and serine-15 phosphorylation in the context of STAT5 signaling. SOCS1 directly interacts with p53 via its SH2 domain (binding the N-terminal transactivation domain of p53), while the SOCS box mediates interaction with DNA damage kinases ATM/ATR. SOCS1 colocalizes with ATM at DNA damage foci. SOCS1 is sufficient to induce p53-dependent senescence in fibroblasts.","method":"Co-immunoprecipitation, immunofluorescence co-localization, p53 activity reporter assays, SOCS1 KO cells, overexpression in fibroblasts","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, colocalization, and functional p53 activity assays with both loss- and gain-of-function approaches","pmids":["20005840"],"is_preprint":false},{"year":2002,"finding":"TRIM8/GERP, a RING finger protein, interacts with SOCS1 in vitro and in vivo. Coexpression of TRIM8/GERP with SOCS1 decreases SOCS1 protein stability and levels, and functionally decreases SOCS1-mediated repression of IFN-γ signaling.","method":"Co-immunoprecipitation, protein stability assays, IFN-γ signaling reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP in vivo plus functional consequence (reduced SOCS1 stability and signaling inhibition), single lab","pmids":["12163497"],"is_preprint":false},{"year":2002,"finding":"Pim serine/threonine kinases interact with SOCS1 in thymocytes; coexpression results in phosphorylation and stabilization of SOCS1 protein. Pim-1/Pim-2 double-knockout mice have significantly reduced SOCS1 protein levels and show prolonged STAT6 phosphorylation upon IL-4 stimulation.","method":"Co-immunoprecipitation, protein stability/phosphorylation assays, Pim-1/Pim-2 double-knockout mouse analysis, STAT6 phosphorylation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP, in vivo mouse KO validation, and functional consequence on STAT6 signaling","pmids":["11854514"],"is_preprint":false},{"year":2004,"finding":"Pim-1 kinase interacts with SOCS1 and SOCS3 and potentiates their inhibitory effects on STAT5, most likely via phosphorylation-mediated stabilization of SOCS proteins. Pim-1 reduced tyrosine phosphorylation and DNA binding of STAT5 in cytokine-responsive cells without directly phosphorylating or binding STAT5.","method":"Co-immunoprecipitation, STAT5 phosphorylation assays, STAT5 DNA-binding assays, ectopic Pim-1 expression","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP with functional STAT5 assays, single lab, mechanism of stabilization inferred rather than directly demonstrated","pmids":["14764533"],"is_preprint":false},{"year":2001,"finding":"SOCS1/JAB associates with both JAK1 and JAK3 in cotransfection experiments, as well as with IL-2Rβ through the A region (residues 313-382). SOCS1 overexpression strongly inhibits IL-2-induced STAT5 phosphorylation and transcriptional activity, with greater effect on JAK1 than JAK3. The IL-2Rβ interaction was not essential for inhibitory action.","method":"Co-immunoprecipitation, STAT5 phosphorylation assays, transcriptional activity assays, deletion mutants","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP with functional STAT5 assays, single lab","pmids":["11133764"],"is_preprint":false},{"year":1997,"finding":"SOCS1/JAB/SSI-1 (identified as TIP3) associates with Tec tyrosine kinase in 293 cells and suppresses its kinase activity, as well as down-regulating JAK2 activity. SOCS1 did not downregulate Lyn kinase activity, demonstrating substrate selectivity.","method":"Yeast two-hybrid screen, co-immunoprecipitation in 293 cells, in vitro kinase assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — yeast two-hybrid plus co-IP and kinase activity assay, single lab","pmids":["9341160"],"is_preprint":false},{"year":2004,"finding":"SOCS1 localizes to the microtubule organizing complex (MTOC) and co-purifies with the MTOC-associated 20S proteasome; this localization requires the SH2 domain of SOCS1. Overexpression of SOCS1 targets JAK1 to a perinuclear distribution resembling the MTOC-associated proteasome. Nocodazole (microtubule depolymerization) inhibits SOCS1 protein turnover, indicating that minus-end transport to the MTOC-associated proteasome regulates SOCS1 levels.","method":"Immunofluorescence colocalization, biochemical co-purification, SH2 domain deletion mutants, nocodazole treatment, fractionation from SOCS1-deficient cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (colocalization, co-purification, KO cells, pharmacological perturbation) in one study","pmids":["15456882"],"is_preprint":false},{"year":2000,"finding":"SOCS1 expression is repressed at the level of translation initiation by the 5' untranslated region, mediated by two upstream AUGs. SOCS1 translation is cap-dependent and modulated by eIF4E-binding proteins.","method":"5'UTR deletion/mutation constructs, translation reporter assays, eIF4E-binding protein manipulation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structure-function analysis with reporter assays, single lab","pmids":["10764816"],"is_preprint":false},{"year":2000,"finding":"SOCS1 can suppress CD3ζ- and Syk-mediated NF-AT activation in non-lymphoid cells by interacting with Syk and with immunoreceptor tyrosine-based activation motifs (ITAMs) in CD3ζ.","method":"Cotransfection in 293T cells, NF-AT reporter assays, co-immunoprecipitation","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP plus functional NF-AT reporter assay, single lab","pmids":["10788618"],"is_preprint":false},{"year":2001,"finding":"A dominant-negative SOCS1 mutant (F59D-JAB) sustained JAK/STAT activation by chelating the Elongin BC complex, thereby destabilizing wild-type JAB and CIS3 (SOCS3). The SOCS box interaction with Elongin BC stabilizes SOCS1 itself; overexpression of Elongin BC canceled F59D-JAB-induced destabilization of wild-type JAB.","method":"Transgenic mice with F59D-JAB, T cell stimulation assays, 293 cell cotransfection, protein stability assays, Elongin BC overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — transgenic mouse model plus cell-based mechanistic assays, single lab","pmids":["11522790"],"is_preprint":false},{"year":2004,"finding":"JAKs (Jak1 and Jak2) bind to TNF receptor-1 (TNFR-1) and are activated by TNF-α. SOCS1 suppresses TNF-α-induced apoptosis by inhibiting JAK activation and caspase activation downstream. In JAK-deficient cell lines, DNA fragmentation and caspase-8 activation by TNF-α are reduced, establishing that JAKs participate in TNF-α-induced apoptosis signaling.","method":"Co-immunoprecipitation (JAK-TNFR1), SOCS1 overexpression, JAK-deficient cell lines, caspase activity assays","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus JAK-deficient cell lines with functional caspase assays, single lab","pmids":["15173123"],"is_preprint":false},{"year":2013,"finding":"SOCS1 promotes nuclear redistribution and K63-ubiquitylation of VHL in response to DNA double-strand breaks. Loss of VHL or VHL mutations that compromise its K63-ubiquitylation attenuates the DNA-damage response, resulting in decreased homologous recombination repair.","method":"Ubiquitylation assays (K63-specific), subcellular fractionation/localization, VHL mutant analysis, DNA repair assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitylation assays with K63-specific analysis plus localization and functional DNA repair readout, single lab","pmids":["23455319"],"is_preprint":false},{"year":2013,"finding":"SOCS1 mediates ubiquitylation and degradation of the GM-CSF receptor β-common (βc) signaling subunit (GMRβc), attenuating GM-CSF-induced downstream signaling.","method":"Ubiquitylation assays, protein degradation assays, signaling readouts (downstream GM-CSF pathway)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ubiquitylation and degradation assays with signaling readout, single lab","pmids":["24086733"],"is_preprint":false},{"year":2012,"finding":"Bcr-Abl tyrosine phosphorylates SOCS1 mainly on Tyr155 and Tyr204, which is associated with SOCS1 binding to Bcr-Abl. This phosphorylation diminishes SOCS1 inhibitory effects on JAK and STAT5 activation. Disruption of SOCS1 tyrosine phosphorylation impaired Bcr-Abl-mediated tumorigenesis in vivo and blocked Bcr-Abl bone marrow transformation.","method":"Mass spectrometry, site-directed mutagenesis, co-immunoprecipitation, STAT5/JAK phosphorylation assays, nude mouse tumorigenesis assay, bone marrow transformation assay","journal":"Neoplasia","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — MS identification of phosphosites, mutagenesis, co-IP, and in vivo tumorigenesis validation","pmids":["22787435"],"is_preprint":false},{"year":2019,"finding":"SOCS1 Y80 in the SH2 domain is phosphorylated by SRC family kinases; phosphomimetic substitution at Y80 inhibits SOCS1-p53 interaction and abolishes p53 transcriptional activity stimulation, growth arrest, and cellular senescence. Mass spectrometry confirmed Y80 phosphorylation in cells. SRC family kinase inhibitors potentiated the SOCS1-p53 pathway. In lymphomas overexpressing SOCS1, constitutive SRC family kinase activation leads to SOCS1 Y80 phosphorylation and cytoplasmic SOCS1 localization.","method":"Mass spectrometry, site-directed mutagenesis (phosphomimetic Y80E), co-immunoprecipitation, p53 transcriptional activity assays, senescence assays, kinase library screen, IHC with phospho-specific antibody","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — MS-confirmed phosphorylation, mutagenesis, kinase library screen, co-IP, and functional senescence assays with in vivo tissue validation","pmids":["31101761"],"is_preprint":false},{"year":2008,"finding":"Glucocorticoid receptor (GR) and SOCS1 form an intracellular complex; the interaction requires the SH2 domain of SOCS1 and the ligand-binding domain of GR. GC stimulation increases nuclear levels of SOCS1. SOCS1 binding to GR negatively influences transcription of GR-regulated genes FKBP5 and MKP1, as shown by IFNγ-induced SOCS1 inhibiting their expression and enhanced expression in SOCS1-deficient fibroblasts.","method":"Co-immunoprecipitation, subcellular fractionation, SH2 domain deletion mutants, SOCS1-deficient MEFs, gene expression assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP with domain mapping and SOCS1 KO functional validation, single lab","pmids":["18524780"],"is_preprint":false},{"year":2017,"finding":"SOCS1 acts as a negative regulator of macrophage metabolic reprogramming during sepsis. Myeloid-specific SOCS1 deletion increases glycolysis (elevated lactic acid, hexokinase, LDHA, GLUT1 expression) in septic macrophages via the STAT3/HIF-1α/glycolysis axis. A SOCS1 KIR-blocking peptide (iKIR) increases CLP-induced mortality, confirming that SOCS1 KIR domain activity is required for this function.","method":"Myeloid-specific conditional SOCS1 knockout mice, cecal ligation and puncture model, metabolic measurements (lactate, glycolytic enzyme expression), KIR peptide inhibitor (iKIR), STAT3/HIF-1α pathway analysis, glycolysis inhibitor rescue","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO mice plus peptide inhibitor with metabolic and pathway rescue experiments","pmids":["28679957"],"is_preprint":false},{"year":2010,"finding":"Threonine phosphorylation of SOCS1 by Pim-1 (induced by Pasteurella multocida Toxin) disrupts SOCS1 E3 ubiquitin ligase activity toward JAK2, preventing JAK2 from being marked for proteasomal degradation. This leads to increased JAK2 and STAT3 activity and increased anchorage-independent growth.","method":"Pim-1 kinase coexpression, SOCS1 phosphorylation analysis, JAK2 ubiquitination/degradation assays, STAT3 activity assays, anchorage-independent growth assay","journal":"Cellular microbiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — mechanistic link between Pim-1 phosphorylation and SOCS1 E3 ligase impairment demonstrated functionally, single lab","pmids":["20633028"],"is_preprint":false},{"year":2008,"finding":"SOCS1 regulates IFN-dependent pathways (IFN-β production and STAT1 phosphorylation) downstream of TLR4 in human monocytes, but does not regulate early NF-κB activation or DNA binding capacity in LPS-stimulated human monocytes.","method":"Adenoviral SOCS1 overexpression in primary human monocytes, NF-κB DNA-binding assays, STAT1 phosphorylation assays, IFN-β mRNA/protein measurement, cytokine ELISA","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — adenoviral overexpression in primary human cells with pathway-specific readouts, single lab","pmids":["19017994"],"is_preprint":false},{"year":2017,"finding":"SOCS1 regulates cellular senescence and ferroptosis through p53 target genes. SOCS1 reduces expression of the cystine transporter SLC7A11 and glutathione levels, sensitizing cells to ferroptosis. This effect requires SOCS1 sufficiency and correlates with its ability to regulate p53 target gene expression.","method":"Transcriptome analysis, SOCS1 overexpression/inhibition, SLC7A11 expression assays, glutathione measurement, ferroptosis assays","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional assays linking SOCS1 to ferroptosis via p53/SLC7A11/glutathione axis, single lab","pmids":["29081404"],"is_preprint":false},{"year":2020,"finding":"Heterozygous germline loss-of-function mutations in SOCS1 cause haploinsufficiency resulting in enhanced STAT1, STAT3 (to a lesser degree), and STAT5/STAT6 activation in patient-derived lymphocytes in response to IFN-γ, IL-2, and IL-4. This enhanced STAT activation was reverted by JAK1/JAK2 inhibitor ruxolitinib, establishing JAK-STAT hyperactivation as the cellular mechanism of disease.","method":"Whole-exome/genome sequencing, patient-derived lymphocyte stimulation assays, STAT phosphorylation assays, JAK inhibitor (ruxolitinib) rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — natural human loss-of-function mutations validated in patient cells with pharmacological rescue, multi-family cohort","pmids":["33087723"],"is_preprint":false},{"year":2008,"finding":"SOCS1 regulates CCR7 expression and T cell trafficking to peripheral tissues. In SOCS1-deficient mice, CCR7 is markedly reduced on T cells correlating with hyperactivation of STAT6. Forced SOCS1 overexpression in T cells upregulates CCR7 and enhances chemotaxis toward CCL19/CCL21. CCR6 and CXCR3 are also upregulated on SOCS1-deficient T cells.","method":"SOCS1 KO, STAT1 KO, STAT6 KO mice; stable SOCS1 overexpression/deletion in T cells; flow cytometry; chemotaxis assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mouse KO models and gain/loss-of-function in T cells with functional chemotaxis readout, single lab","pmids":["18606672"],"is_preprint":false}],"current_model":"SOCS1 is a negative-feedback regulator of JAK-STAT and related signaling pathways that operates through multiple distinct mechanisms: (1) direct inhibition of JAK catalytic activity via its kinase inhibitory region (KIR), which binds the phosphorylated activation loop (Y1007) of JAK2 with its extended SH2 domain and pseudosubstrate-like KIR motif; (2) E3 ubiquitin ligase activity, scaffolded by its SOCS box engaging Elongin B/C and Cullin-2/5, which ubiquitinates substrates including activated JAK2, IRS1/2, GMR-βc, and VHL for proteasomal degradation; (3) tumor suppressor functions through direct SH2-domain interaction with the p53 transactivation domain and SOCS-box-mediated engagement of ATM/ATR, enabling p53 activation and senescence; (4) regulation of its own stability and activity by post-translational modifications—Pim kinases phosphorylate and stabilize SOCS1, while SRC family kinases phosphorylate Y80 in the SH2 domain to block p53 interaction and cytoplasmic sequestration, and Bcr-Abl phosphorylates Y155/Y204 to inactivate its inhibitory function; (5) translational repression via upstream AUGs in its 5'UTR; and (6) localization to the MTOC-associated 20S proteasome via its SH2 domain, linking it directly to the proteasome pathway."},"narrative":{"mechanistic_narrative":"SOCS1 is a cytokine-inducible negative-feedback regulator of JAK-STAT signaling that operates as both a direct kinase inhibitor and a substrate-recruiting component of an E3 ubiquitin ligase [PMID:10064597, PMID:9789053, PMID:9716595]. Its core inhibitory mechanism couples an extended SH2 domain, which binds the phosphorylated activation-loop tyrosine (Y1007) of JAK2, to an adjacent kinase inhibitory region (KIR) that occupies the substrate-binding groove of the JAK catalytic domain to block phosphorylation [PMID:10064597, PMID:29674694]. Strongly induced by IFN-γ, SOCS1 thereby suppresses JAK1/JAK2 activation, STAT1 tyrosine phosphorylation, and the antiviral response [PMID:9716595], and analogous inhibition extends to JAK3/IL-2Rβ-driven STAT5 signaling [PMID:11133764]. In parallel, SOCS1 functions as an adaptor of a Cullin-Elongin BC E3 ligase: its SOCS box engages Elongin B/C and Cullin-2, while the SH2 domain selects substrates for K48-linked ubiquitination and proteasomal degradation, including IRS1/IRS2, the leukemic fusion TEL-JAK2, and the GM-CSF receptor βc subunit [PMID:12228220, PMID:11278610, PMID:24086733]. Beyond cytokine signaling, SOCS1 acts as a tumor suppressor by binding the p53 transactivation domain through its SH2 domain and engaging ATM/ATR through its SOCS box to drive p53 phosphorylation, transcriptional activity, and senescence, and it also directs K63-ubiquitylation of VHL to support DNA double-strand-break repair [PMID:20005840, PMID:23455319]. SOCS1 abundance and activity are tightly tuned post-transcriptionally: SOCS box-Elongin BC engagement stabilizes the protein [PMID:9789053, PMID:11522790], translation is repressed by upstream AUGs in its 5'UTR [PMID:10764816], and turnover is linked to MTOC-associated 20S proteasome localization via the SH2 domain [PMID:15456882]. Pim kinases phosphorylate and stabilize SOCS1 to potentiate STAT inhibition [PMID:11854514], whereas SRC-family phosphorylation of Y80 blocks the p53 interaction and drives cytoplasmic sequestration, and Bcr-Abl phosphorylation of Y155/Y204 inactivates JAK/STAT inhibition to promote transformation [PMID:31101761, PMID:22787435]. Heterozygous germline loss-of-function mutations in SOCS1 cause an autoimmune/inflammatory disorder of JAK-STAT hyperactivation reversible by ruxolitinib [PMID:33087723].","teleology":[{"year":1999,"claim":"Established the molecular basis of JAK inhibition: how SOCS1 recognizes an active kinase and shuts it off.","evidence":"In vitro binding and kinase assays with site-directed mutagenesis mapping SH2/extended-SH2 and KIR contacts on JAK2 Y1007","pmids":["10064597"],"confidence":"High","gaps":["Inhibition demonstrated for JAK2; specificity across all JAK family members not fully resolved in this study","No high-resolution co-structure provided at this stage"]},{"year":1998,"claim":"Defined the modular domain architecture (pre-SH2, SH2, SOCS box) required for cytokine suppression and protein stability, clarifying division of labor within SOCS1.","evidence":"Deletion mutagenesis with co-IP, reporter assays, and proteasome inhibition in the IL-6 system","pmids":["9789053"],"confidence":"High","gaps":["SOCS box partner identity (Elongin BC) inferred, not yet biochemically defined here","Did not resolve which JAK is the principal physiological target"]},{"year":1998,"claim":"Connected SOCS1 to a physiological feedback loop, showing IFN-induced SOCS1 confers cytokine/antiviral resistance via JAK-STAT1 blockade.","evidence":"Stable overexpression with kinase, STAT1 phosphorylation/DNA-binding, and antiviral assays","pmids":["9716595"],"confidence":"High","gaps":["Constitutive SOCS1 in IFN-resistant tumors observational, not causally tested","Endogenous induction kinetics not dissected"]},{"year":2001,"claim":"Revealed SOCS1 is not only a kinase blocker but an E3 ligase adaptor, recruiting Cullin-2/Elongin BC to ubiquitinate and degrade phosphorylated JAK substrates.","evidence":"Ubiquitination assays, dominant-negative Cullin-2 rescue, and proteasome inhibition on TEL-JAK2","pmids":["11278610"],"confidence":"High","gaps":["Demonstrated on a leukemic fusion; degradation of native full-length JAK2 generality not fully established","Stoichiometry and chain linkage not characterized"]},{"year":2002,"claim":"Extended the ligase mechanism to metabolic signaling, showing SOCS1 targets IRS1/IRS2 for degradation with in vivo physiological consequence.","evidence":"Co-IP, ubiquitination assays, SOCS box mutagenesis, and adenoviral SOCS1 expression in mouse liver with glucose tolerance testing","pmids":["12228220"],"confidence":"High","gaps":["Adenoviral overexpression may exceed physiological levels","Did not separate degradation from kinase-inhibitory contributions to glucose intolerance"]},{"year":2002,"claim":"Placed SOCS1 in innate immune feedback, demonstrating it restrains LPS-driven NF-κB/STAT1 activation and is required for endotoxin tolerance.","evidence":"SOCS1 knockout mice, macrophage stimulation, and forced expression with NF-κB/STAT1 readouts","pmids":["12433373","12433365"],"confidence":"High","gaps":["Direct molecular target on the TLR4 pathway not defined here","NF-κB regulation later found cell-type dependent"]},{"year":2002,"claim":"Identified Pim kinases as positive regulators that phosphorylate and stabilize SOCS1, defining a kinase-controlled input to feedback strength.","evidence":"Co-IP, phosphorylation/stability assays, and Pim-1/Pim-2 double-knockout mice with STAT6 readout","pmids":["11854514"],"confidence":"High","gaps":["Phosphosites on SOCS1 not mapped here","Mechanism linking phosphorylation to stabilization inferred"]},{"year":2004,"claim":"Defined the cellular geography of SOCS1 turnover, localizing it to the MTOC-associated 20S proteasome via its SH2 domain.","evidence":"Immunofluorescence colocalization, co-purification, SH2 deletion, and nocodazole perturbation in SOCS1-deficient cells","pmids":["15456882"],"confidence":"High","gaps":["Functional necessity of MTOC localization for substrate degradation not established","Transport machinery for minus-end delivery not identified"]},{"year":2009,"claim":"Uncovered a tumor-suppressor mechanism distinct from cytokine signaling: SOCS1 directly engages p53 and ATM/ATR to drive p53 activation and senescence.","evidence":"Reciprocal co-IP, DNA-damage foci colocalization, p53 reporter assays, and loss/gain-of-function in fibroblasts","pmids":["20005840"],"confidence":"High","gaps":["Whether SOCS1 ligase activity acts on p53/ATM substrates not resolved here","Link to STAT5 context-dependency incompletely mapped"]},{"year":2012,"claim":"Showed oncogenic kinases can inactivate SOCS1, with Bcr-Abl phosphorylating Y155/Y204 to disable JAK/STAT inhibition and enable transformation.","evidence":"Mass spectrometry, mutagenesis, co-IP, STAT5/JAK assays, and in vivo tumorigenesis/bone marrow transformation","pmids":["22787435"],"confidence":"High","gaps":["Structural basis of how Y155/Y204 phosphorylation disrupts KIR/SH2 function not defined","Contribution of degradation versus kinase inhibition to the rescued phenotype unclear"]},{"year":2013,"claim":"Expanded the ligase output to the DNA-damage response, showing SOCS1 directs K63-ubiquitylation and nuclear redistribution of VHL to support homologous recombination.","evidence":"K63-specific ubiquitylation assays, localization, VHL mutant analysis, and DNA repair readouts","pmids":["23455319"],"confidence":"Medium","gaps":["Single lab; reciprocal validation limited","How SOCS1 switches from K48-degradative to K63-signaling ubiquitination not explained"]},{"year":2017,"claim":"Linked SOCS1's KIR-dependent activity to control of macrophage metabolic reprogramming via the STAT3/HIF-1α/glycolysis axis during sepsis.","evidence":"Myeloid-specific SOCS1 knockout, CLP sepsis model, metabolic measurements, and KIR-blocking peptide (iKIR)","pmids":["28679957"],"confidence":"High","gaps":["Direct kinase target driving STAT3/HIF-1α not pinpointed","Whether ligase activity contributes alongside KIR not tested"]},{"year":2019,"claim":"Defined a switch governing SOCS1's tumor-suppressor arm: SRC-family phosphorylation of Y80 blocks p53 binding and drives cytoplasmic SOCS1 in lymphoma.","evidence":"Mass spectrometry, Y80E phosphomimetic mutagenesis, kinase library screen, co-IP, senescence assays, and IHC","pmids":["31101761"],"confidence":"High","gaps":["Whether Y80 phosphorylation also alters JAK inhibition not addressed","Reversibility/phosphatase regulation of Y80 not defined"]},{"year":2020,"claim":"Established human disease relevance: SOCS1 haploinsufficiency causes JAK-STAT hyperactivation reversible by JAK inhibition.","evidence":"Exome/genome sequencing of patients, lymphocyte STAT phosphorylation assays, and ruxolitinib rescue","pmids":["33087723"],"confidence":"High","gaps":["Genotype-phenotype variability across families not fully explained","Which downstream STAT dominates pathology not resolved"]},{"year":null,"claim":"How SOCS1 partitions between its kinase-inhibitory, K48-degradative, and K63-signaling/p53 tumor-suppressor functions in a given cell, and what dictates substrate and ubiquitin-linkage choice, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model integrating direct inhibition versus ligase versus p53 functions","Regulation of ubiquitin chain-type choice (K48 vs K63) unknown","In vivo balance of these arms across tissues not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,5]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[3,4,18,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,5,11,16]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[3,4,7]}],"localization":[{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13,21]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,23,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,4,19]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[18]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[17,26]}],"complexes":["Elongin BC-Cullin-2 E3 ubiquitin ligase","MTOC-associated 20S proteasome"],"partners":["JAK2","JAK1","TYK2","ELONGIN B/C","CULLIN-2","TP53","PIM-1","VHL"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15524","full_name":"Suppressor of cytokine signaling 1","aliases":["JAK-binding protein","JAB","STAT-induced STAT inhibitor 1","SSI-1","Tec-interacting protein 3","TIP-3"],"length_aa":211,"mass_kda":23.6,"function":"Essential negative regulator of type I and type II interferon (IFN) signaling, as well as that of other cytokines, including IL2, IL4, IL6 and leukemia inhibitory factor (LIF) (PubMed:32499645, PubMed:33087723). Downregulates cytokine signaling by inhibiting the JAK/STAT signaling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity (PubMed:9341160). Regulates IFN-gamma (IFNG)-mediated sensory neuron survival (By similarity). Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:11278610, PubMed:11313480)","subcellular_location":"Nucleus; Cytoplasmic vesicle","url":"https://www.uniprot.org/uniprotkb/O15524/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOCS1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOCS1","total_profiled":1310},"omim":[{"mim_id":"621321","title":"KIAA0087 LONG NONCODING RNA; KIAA0087","url":"https://www.omim.org/entry/621321"},{"mim_id":"619428","title":"FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND NEURODEVELOPMENTAL SYNDROME; FSGSNEDS","url":"https://www.omim.org/entry/619428"},{"mim_id":"619375","title":"AUTOINFLAMMATORY SYNDROME, FAMILIAL, WITH OR WITHOUT IMMUNODEFICIENCY; AISIMD","url":"https://www.omim.org/entry/619375"},{"mim_id":"612472","title":"METHYLTRANSFERASE 3, N6-ADENOSINE-METHYLTRANSFERASE COMPLEX CATALYTIC SUBUNIT; METTL3","url":"https://www.omim.org/entry/612472"},{"mim_id":"610562","title":"ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 12A; ZC3H12A","url":"https://www.omim.org/entry/610562"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SOCS1"},"hgnc":{"alias_symbol":["SOCS-1","SSI-1","JAB","TIP3","Cish1"],"prev_symbol":[]},"alphafold":{"accession":"O15524","domains":[{"cath_id":"3.30.505.10","chopping":"62-171","consensus_level":"high","plddt":94.3764,"start":62,"end":171},{"cath_id":"1.10.10","chopping":"172-211","consensus_level":"medium","plddt":93.807,"start":172,"end":211}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15524","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15524-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15524-F1-predicted_aligned_error_v6.png","plddt_mean":83.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOCS1","jax_strain_url":"https://www.jax.org/strain/search?query=SOCS1"},"sequence":{"accession":"O15524","fasta_url":"https://rest.uniprot.org/uniprotkb/O15524.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15524/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15524"}},"corpus_meta":[{"pmid":"12228220","id":"PMC_12228220","title":"SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12228220","citation_count":702,"is_preprint":false},{"pmid":"10064597","id":"PMC_10064597","title":"The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10064597","citation_count":584,"is_preprint":false},{"pmid":"12433373","id":"PMC_12433373","title":"SOCS-1 participates in negative regulation of LPS responses.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12433373","citation_count":517,"is_preprint":false},{"pmid":"12433365","id":"PMC_12433365","title":"SOCS1/JAB is a negative regulator of LPS-induced macrophage activation.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12433365","citation_count":505,"is_preprint":false},{"pmid":"29674694","id":"PMC_29674694","title":"The molecular basis of JAK/STAT inhibition by SOCS1.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29674694","citation_count":373,"is_preprint":false},{"pmid":"11278610","id":"PMC_11278610","title":"The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278610","citation_count":264,"is_preprint":false},{"pmid":"19643666","id":"PMC_19643666","title":"SOCS1 and SOCS3 in the control of CNS immunity.","date":"2009","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19643666","citation_count":237,"is_preprint":false},{"pmid":"9789053","id":"PMC_9789053","title":"Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9789053","citation_count":195,"is_preprint":false},{"pmid":"11854514","id":"PMC_11854514","title":"Pim serine/threonine kinases regulate the stability of Socs-1 protein.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11854514","citation_count":167,"is_preprint":false},{"pmid":"9716595","id":"PMC_9716595","title":"A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9716595","citation_count":160,"is_preprint":false},{"pmid":"15197228","id":"PMC_15197228","title":"SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis.","date":"2004","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15197228","citation_count":159,"is_preprint":false},{"pmid":"10201892","id":"PMC_10201892","title":"Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10201892","citation_count":134,"is_preprint":false},{"pmid":"33087723","id":"PMC_33087723","title":"Early-onset autoimmunity associated with SOCS1 haploinsufficiency.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33087723","citation_count":125,"is_preprint":false},{"pmid":"20005840","id":"PMC_20005840","title":"SOCS1 links cytokine signaling to p53 and senescence.","date":"2009","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/20005840","citation_count":122,"is_preprint":false},{"pmid":"18713987","id":"PMC_18713987","title":"Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18713987","citation_count":112,"is_preprint":false},{"pmid":"11133764","id":"PMC_11133764","title":"JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11133764","citation_count":110,"is_preprint":false},{"pmid":"12080466","id":"PMC_12080466","title":"The tumor suppressor activity of SOCS-1.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12080466","citation_count":108,"is_preprint":false},{"pmid":"14764533","id":"PMC_14764533","title":"Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14764533","citation_count":106,"is_preprint":false},{"pmid":"28901399","id":"PMC_28901399","title":"Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28901399","citation_count":101,"is_preprint":false},{"pmid":"17204547","id":"PMC_17204547","title":"IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro.","date":"2007","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17204547","citation_count":101,"is_preprint":false},{"pmid":"12163497","id":"PMC_12163497","title":"TRIM8/GERP RING finger protein interacts with SOCS-1.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12163497","citation_count":98,"is_preprint":false},{"pmid":"16451196","id":"PMC_16451196","title":"SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16451196","citation_count":96,"is_preprint":false},{"pmid":"9341160","id":"PMC_9341160","title":"SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9341160","citation_count":95,"is_preprint":false},{"pmid":"29081404","id":"PMC_29081404","title":"SOCS1 regulates senescence and ferroptosis by modulating the expression of p53 target genes.","date":"2017","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/29081404","citation_count":91,"is_preprint":false},{"pmid":"17438093","id":"PMC_17438093","title":"Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17438093","citation_count":86,"is_preprint":false},{"pmid":"22025331","id":"PMC_22025331","title":"Role of SOCS1 in tumor progression and therapeutic application.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22025331","citation_count":73,"is_preprint":false},{"pmid":"17376806","id":"PMC_17376806","title":"Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma.","date":"2007","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/17376806","citation_count":72,"is_preprint":false},{"pmid":"15373779","id":"PMC_15373779","title":"Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15373779","citation_count":69,"is_preprint":false},{"pmid":"31105556","id":"PMC_31105556","title":"Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31105556","citation_count":66,"is_preprint":false},{"pmid":"26811119","id":"PMC_26811119","title":"SOCS1 in cancer: An oncogene and a tumor suppressor.","date":"2016","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26811119","citation_count":63,"is_preprint":false},{"pmid":"11522790","id":"PMC_11522790","title":"A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11522790","citation_count":59,"is_preprint":false},{"pmid":"10764816","id":"PMC_10764816","title":"Regulation of SOCS-1 expression by translational repression.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10764816","citation_count":58,"is_preprint":false},{"pmid":"12670405","id":"PMC_12670405","title":"Regulation of cytokine receptor signaling by SOCS1.","date":"2003","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12670405","citation_count":54,"is_preprint":false},{"pmid":"15121754","id":"PMC_15121754","title":"Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers.","date":"2004","source":"Japanese journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15121754","citation_count":50,"is_preprint":false},{"pmid":"10630404","id":"PMC_10630404","title":"SOCS-1, -2, -3: selective targets and functions downstream of the prolactin receptor.","date":"1999","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/10630404","citation_count":49,"is_preprint":false},{"pmid":"19017994","id":"PMC_19017994","title":"SOCS1 regulates the IFN but not NFkappaB pathway in TLR-stimulated human monocytes and macrophages.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19017994","citation_count":49,"is_preprint":false},{"pmid":"12183076","id":"PMC_12183076","title":"Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12183076","citation_count":47,"is_preprint":false},{"pmid":"10788618","id":"PMC_10788618","title":"SOCS-1 can suppress CD3zeta- and Syk-mediated NF-AT activation in a non-lymphoid cell line.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10788618","citation_count":47,"is_preprint":false},{"pmid":"9844915","id":"PMC_9844915","title":"The CIS/JAB family: novel negative regulators of JAK signaling pathways.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9844915","citation_count":45,"is_preprint":false},{"pmid":"30811476","id":"PMC_30811476","title":"Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30811476","citation_count":45,"is_preprint":false},{"pmid":"15456882","id":"PMC_15456882","title":"SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15456882","citation_count":44,"is_preprint":false},{"pmid":"23621248","id":"PMC_23621248","title":"miR-19a promotes cell growth and tumorigenesis through targeting SOCS1 in gastric cancer.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23621248","citation_count":44,"is_preprint":false},{"pmid":"15173123","id":"PMC_15173123","title":"SOCS-1 suppresses TNF-alpha-induced apoptosis through the regulation of Jak activation.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15173123","citation_count":41,"is_preprint":false},{"pmid":"23455319","id":"PMC_23455319","title":"K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23455319","citation_count":40,"is_preprint":false},{"pmid":"20648401","id":"PMC_20648401","title":"Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma.","date":"2010","source":"Swiss medical weekly","url":"https://pubmed.ncbi.nlm.nih.gov/20648401","citation_count":40,"is_preprint":false},{"pmid":"28679957","id":"PMC_28679957","title":"SOCS1 is a negative regulator of metabolic reprogramming during sepsis.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28679957","citation_count":38,"is_preprint":false},{"pmid":"28781601","id":"PMC_28781601","title":"Resveratrol Attenuates Microglial Activation via SIRT1-SOCS1 Pathway.","date":"2017","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/28781601","citation_count":37,"is_preprint":false},{"pmid":"21872343","id":"PMC_21872343","title":"Expression of SOCS1-7 and CIS mRNA in porcine tissues.","date":"2011","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/21872343","citation_count":37,"is_preprint":false},{"pmid":"32173492","id":"PMC_32173492","title":"lncRNA TUG1 regulates ulcerative colitis through miR-142-5p/SOCS1 axis.","date":"2020","source":"Microbial pathogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32173492","citation_count":36,"is_preprint":false},{"pmid":"19561639","id":"PMC_19561639","title":"SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19561639","citation_count":36,"is_preprint":false},{"pmid":"24882063","id":"PMC_24882063","title":"Resveratrol counteracts lipopolysaccharide-mediated microglial inflammation by modulating a SOCS-1 dependent signaling pathway.","date":"2014","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/24882063","citation_count":36,"is_preprint":false},{"pmid":"31154249","id":"PMC_31154249","title":"Hepatocyte growth control by SOCS1 and SOCS3.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31154249","citation_count":34,"is_preprint":false},{"pmid":"20372794","id":"PMC_20372794","title":"Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20372794","citation_count":34,"is_preprint":false},{"pmid":"11032030","id":"PMC_11032030","title":"The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11032030","citation_count":33,"is_preprint":false},{"pmid":"22787435","id":"PMC_22787435","title":"A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22787435","citation_count":33,"is_preprint":false},{"pmid":"11304496","id":"PMC_11304496","title":"Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11304496","citation_count":33,"is_preprint":false},{"pmid":"30761449","id":"PMC_30761449","title":"SOCS1 and its Potential Clinical Role in Tumor.","date":"2019","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/30761449","citation_count":32,"is_preprint":false},{"pmid":"28900678","id":"PMC_28900678","title":"SOCS1: Regulator of T Cells in Autoimmunity and Cancer.","date":"2017","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28900678","citation_count":32,"is_preprint":false},{"pmid":"30048621","id":"PMC_30048621","title":"A cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis.","date":"2018","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/30048621","citation_count":32,"is_preprint":false},{"pmid":"24480984","id":"PMC_24480984","title":"Respiratory syncytial virus NS1 protein degrades STAT2 by inducing SOCS1 expression.","date":"2014","source":"Intervirology","url":"https://pubmed.ncbi.nlm.nih.gov/24480984","citation_count":31,"is_preprint":false},{"pmid":"11314018","id":"PMC_11314018","title":"The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11314018","citation_count":31,"is_preprint":false},{"pmid":"17045460","id":"PMC_17045460","title":"SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes.","date":"2006","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/17045460","citation_count":30,"is_preprint":false},{"pmid":"37842165","id":"PMC_37842165","title":"A mutual regulatory loop between miR-155 and SOCS1 influences renal inflammation and diabetic kidney disease.","date":"2023","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/37842165","citation_count":30,"is_preprint":false},{"pmid":"33717088","id":"PMC_33717088","title":"Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33717088","citation_count":30,"is_preprint":false},{"pmid":"31876380","id":"PMC_31876380","title":"Human microRNA-30 inhibits influenza virus infection by suppressing the expression of SOCS1, SOCS3, and NEDD4.","date":"2019","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31876380","citation_count":30,"is_preprint":false},{"pmid":"18330685","id":"PMC_18330685","title":"SOCS-1 inhibits TNF-alpha-induced cardiomyocyte apoptosis via ERK1/2 pathway activation.","date":"2008","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/18330685","citation_count":29,"is_preprint":false},{"pmid":"26391193","id":"PMC_26391193","title":"Tumour-promoting role of SOCS1 in colorectal cancer cells.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26391193","citation_count":29,"is_preprint":false},{"pmid":"17198680","id":"PMC_17198680","title":"Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17198680","citation_count":29,"is_preprint":false},{"pmid":"34275119","id":"PMC_34275119","title":"IFN-γ inhibits ovarian cancer progression via SOCS1/JAK/STAT signaling pathway.","date":"2021","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/34275119","citation_count":28,"is_preprint":false},{"pmid":"36263168","id":"PMC_36263168","title":"N6-methyladenosine of Socs1 modulates macrophage inflammatory response in different stiffness environments.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36263168","citation_count":28,"is_preprint":false},{"pmid":"34421895","id":"PMC_34421895","title":"One Gene, Many Facets: Multiple Immune Pathway Dysregulation in SOCS1 Haploinsufficiency.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34421895","citation_count":26,"is_preprint":false},{"pmid":"18524780","id":"PMC_18524780","title":"Interaction and functional interference of glucocorticoid receptor and SOCS1.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18524780","citation_count":26,"is_preprint":false},{"pmid":"29907905","id":"PMC_29907905","title":"SOCS-1 Suppresses Inflammation Through Inhibition of NALP3 Inflammasome Formation in Smoke Inhalation-Induced Acute Lung Injury.","date":"2018","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/29907905","citation_count":26,"is_preprint":false},{"pmid":"25133199","id":"PMC_25133199","title":"SOCS1 and regulation of regulatory T cells plasticity.","date":"2014","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25133199","citation_count":25,"is_preprint":false},{"pmid":"26990535","id":"PMC_26990535","title":"miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.","date":"2016","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/26990535","citation_count":25,"is_preprint":false},{"pmid":"10811447","id":"PMC_10811447","title":"The janus kinase inhibitor, Jab/SOCS-1, is an interferon-gamma inducible gene and determines the sensitivity to interferons.","date":"2000","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10811447","citation_count":24,"is_preprint":false},{"pmid":"38975347","id":"PMC_38975347","title":"SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38975347","citation_count":23,"is_preprint":false},{"pmid":"29916533","id":"PMC_29916533","title":"Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29916533","citation_count":23,"is_preprint":false},{"pmid":"27798161","id":"PMC_27798161","title":"TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27798161","citation_count":23,"is_preprint":false},{"pmid":"21461173","id":"PMC_21461173","title":"Role of SOCS-1 Gene on Melanoma Cell Growth and Tumor Development.","date":"2011","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21461173","citation_count":22,"is_preprint":false},{"pmid":"33830082","id":"PMC_33830082","title":"miR-122 promotes virus-induced lung disease by targeting SOCS1.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33830082","citation_count":22,"is_preprint":false},{"pmid":"28842216","id":"PMC_28842216","title":"Egr2 enhances insulin resistance via JAK2/STAT3/SOCS-1 pathway in HepG2 cells treated with palmitate.","date":"2017","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28842216","citation_count":22,"is_preprint":false},{"pmid":"23545584","id":"PMC_23545584","title":"Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in atherosclerosis.","date":"2013","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23545584","citation_count":22,"is_preprint":false},{"pmid":"24086733","id":"PMC_24086733","title":"SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24086733","citation_count":20,"is_preprint":false},{"pmid":"30689554","id":"PMC_30689554","title":"RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.","date":"2019","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/30689554","citation_count":20,"is_preprint":false},{"pmid":"25399770","id":"PMC_25399770","title":"A MyD88-JAK1-STAT1 complex directly induces SOCS-1 expression in macrophages infected with Group A Streptococcus.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25399770","citation_count":20,"is_preprint":false},{"pmid":"18606672","id":"PMC_18606672","title":"SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18606672","citation_count":19,"is_preprint":false},{"pmid":"27133036","id":"PMC_27133036","title":"Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27133036","citation_count":19,"is_preprint":false},{"pmid":"31101761","id":"PMC_31101761","title":"Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31101761","citation_count":17,"is_preprint":false},{"pmid":"39110625","id":"PMC_39110625","title":"Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39110625","citation_count":17,"is_preprint":false},{"pmid":"33585275","id":"PMC_33585275","title":"MicroRNA-30e-5p Regulates SOCS1 and SOCS3 During Bacterial Infection.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33585275","citation_count":17,"is_preprint":false},{"pmid":"18929539","id":"PMC_18929539","title":"SOCS-1 deficiency does not prevent diet-induced insulin resistance.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18929539","citation_count":17,"is_preprint":false},{"pmid":"31407320","id":"PMC_31407320","title":"The impact of SOCS1 mutations in diffuse large B-cell lymphoma.","date":"2019","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/31407320","citation_count":17,"is_preprint":false},{"pmid":"20633028","id":"PMC_20633028","title":"Pasteurella multocida Toxin-induced Pim-1 expression disrupts suppressor of cytokine signalling (SOCS)-1 activity.","date":"2010","source":"Cellular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/20633028","citation_count":17,"is_preprint":false},{"pmid":"32670294","id":"PMC_32670294","title":"Identification of a Human SOCS1 Polymorphism That Predicts Rheumatoid Arthritis Severity.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32670294","citation_count":17,"is_preprint":false},{"pmid":"36765862","id":"PMC_36765862","title":"SOCS1 Deficiency Promotes Hepatocellular Carcinoma via SOCS3-Dependent CDKN1A Induction and NRF2 Activation.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36765862","citation_count":16,"is_preprint":false},{"pmid":"26502748","id":"PMC_26502748","title":"miR-19a and SOCS-1 expression in the differential diagnosis of laryngeal (glottic) verrucous squamous cell carcinoma.","date":"2015","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26502748","citation_count":16,"is_preprint":false},{"pmid":"28235401","id":"PMC_28235401","title":"Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.","date":"2017","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28235401","citation_count":16,"is_preprint":false},{"pmid":"33869908","id":"PMC_33869908","title":"miR-155-5p predictive role to decelerate foam cell atherosclerosis through CD36, VAV3, and SOCS1 pathway.","date":"2021","source":"Non-coding RNA research","url":"https://pubmed.ncbi.nlm.nih.gov/33869908","citation_count":16,"is_preprint":false},{"pmid":"16247220","id":"PMC_16247220","title":"SOCS1/JAB likely mediates the protective effect of cardiotrophin-1 against lipopolysaccharide-induced left ventricular dysfunction in vivo.","date":"2005","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/16247220","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49662,"output_tokens":7723,"usd":0.132415,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17036,"output_tokens":4945,"usd":0.104402,"stage2_stop_reason":"end_turn"},"total_usd":0.236817,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"SOCS1/JAB binds specifically to the phosphorylated tyrosine residue Y1007 in the activation loop of JAK2, requiring both the SH2 domain and an N-terminal extended SH2 subdomain (containing Ile68 and Leu75). An additional kinase inhibitory region (KIR) contributes to high-affinity binding to the JAK2 kinase domain and is required for inhibition of JAK2 signaling and kinase activity.\",\n      \"method\": \"In vitro binding assays, site-directed mutagenesis, kinase activity assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis defining binding residues and kinase inhibition mechanism; foundational mechanistic paper\",\n      \"pmids\": [\"10064597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal/structural studies revealed that the SOCS1 kinase inhibitory region (KIR) targets the substrate-binding groove of JAK with high specificity to block phosphorylation. SOCS1 has a compromised ability to recruit Cullin5 due to alterations within its SOCS box domain, making direct JAK catalytic inhibition its primary mode of action. SOCS1 does not bind the IFNγ receptor, distinguishing its mechanism from SOCS3.\",\n      \"method\": \"Structural determination (crystallography/biophysical), in vitro kinase assays, mutagenesis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural determination combined with functional validation and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"29674694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Three distinct domains of SOCS1/SSI-1 are required for suppression of IL-6 signaling: (1) the pre-SH2 domain (24 aa N-terminal to the SH2 domain), (2) the SH2 domain (required for association with JAK family kinases including JAK1, JAK2, TYK2), and (3) the SC-motif (SOCS box), which protects SOCS1 from proteasomal degradation. Deletion of the SH2 domain abolished co-association with TYK2.\",\n      \"method\": \"Deletion mutagenesis, co-expression/co-immunoprecipitation, reporter assays, proteasome inhibitor treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple domain deletion mutants tested with orthogonal assays (reporter, co-IP, proteasome inhibition) in one study\",\n      \"pmids\": [\"9789053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SOCS1 and SOCS3 bind both recombinant and endogenous IRS1 and IRS2, promote their ubiquitination and subsequent proteasomal degradation. Mutations in the conserved SOCS box of SOCS1 abrogated interaction with the elongin BC ubiquitin-ligase complex without affecting IRS1/IRS2 binding, and abolished ubiquitination and degradation. Adenoviral expression of SOCS1 in mouse liver dramatically reduced hepatic IRS1 and IRS2 protein levels and caused glucose intolerance.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, SOCS box mutagenesis, adenoviral gene delivery in mice, glucose tolerance testing\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (co-IP, ubiquitination assay, mutagenesis, in vivo mouse model) in one study\",\n      \"pmids\": [\"12228220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The SOCS box of SOCS1 interacts with Cullin-2 (in addition to Elongin B/C) and promotes ubiquitination of the leukemic fusion protein TEL-JAK2, leading to its proteasomal degradation. Dominant-negative Cullin-2 suppressed SOCS1-dependent TEL-JAK2 degradation. Degradation required JAK2 phosphorylation and high-affinity binding through the KIR and SH2 domain of SOCS1.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, dominant-negative Cullin-2 overexpression, proteasome inhibitor experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstitution of ubiquitin ligase activity with multiple orthogonal approaches including dominant-negative rescue\",\n      \"pmids\": [\"11278610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"JAB/SOCS1 is strongly induced by IFN-γ; forced expression of JAB confers resistance to IFN-β and IFN-γ by inhibiting JAK1 and JAK2 activation and blocking STAT1 tyrosine phosphorylation and DNA-binding activity. IFN-resistant tumor cell clones expressed high constitutive levels of JAB.\",\n      \"method\": \"Stable cell line overexpression, antiviral assay, kinase activity assay, STAT1 phosphorylation and DNA-binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple functional assays (kinase, STAT phosphorylation, antiviral) in stable cell lines; independently corroborated by other papers\",\n      \"pmids\": [\"9716595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SOCS1 expression is rapidly induced in macrophages by LPS. SOCS1 deficiency increases sensitivity to LPS-induced shock and augments inflammatory cytokine production. Forced SOCS1 expression inhibits LPS-induced NF-κB and STAT1 activation. SOCS1-deficient mice fail to develop LPS tolerance.\",\n      \"method\": \"SOCS1 knockout mice, macrophage stimulation assays, NF-κB and STAT1 reporter/phosphorylation assays, forced SOCS1 expression\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated independently in two concurrent papers (PMID 12433373 and 12433365) using KO mice and overexpression with consistent findings\",\n      \"pmids\": [\"12433373\", \"12433365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SOCS1 is required for p53 transcriptional activity, DNA binding, and serine-15 phosphorylation in the context of STAT5 signaling. SOCS1 directly interacts with p53 via its SH2 domain (binding the N-terminal transactivation domain of p53), while the SOCS box mediates interaction with DNA damage kinases ATM/ATR. SOCS1 colocalizes with ATM at DNA damage foci. SOCS1 is sufficient to induce p53-dependent senescence in fibroblasts.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, p53 activity reporter assays, SOCS1 KO cells, overexpression in fibroblasts\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, colocalization, and functional p53 activity assays with both loss- and gain-of-function approaches\",\n      \"pmids\": [\"20005840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TRIM8/GERP, a RING finger protein, interacts with SOCS1 in vitro and in vivo. Coexpression of TRIM8/GERP with SOCS1 decreases SOCS1 protein stability and levels, and functionally decreases SOCS1-mediated repression of IFN-γ signaling.\",\n      \"method\": \"Co-immunoprecipitation, protein stability assays, IFN-γ signaling reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP in vivo plus functional consequence (reduced SOCS1 stability and signaling inhibition), single lab\",\n      \"pmids\": [\"12163497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Pim serine/threonine kinases interact with SOCS1 in thymocytes; coexpression results in phosphorylation and stabilization of SOCS1 protein. Pim-1/Pim-2 double-knockout mice have significantly reduced SOCS1 protein levels and show prolonged STAT6 phosphorylation upon IL-4 stimulation.\",\n      \"method\": \"Co-immunoprecipitation, protein stability/phosphorylation assays, Pim-1/Pim-2 double-knockout mouse analysis, STAT6 phosphorylation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP, in vivo mouse KO validation, and functional consequence on STAT6 signaling\",\n      \"pmids\": [\"11854514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pim-1 kinase interacts with SOCS1 and SOCS3 and potentiates their inhibitory effects on STAT5, most likely via phosphorylation-mediated stabilization of SOCS proteins. Pim-1 reduced tyrosine phosphorylation and DNA binding of STAT5 in cytokine-responsive cells without directly phosphorylating or binding STAT5.\",\n      \"method\": \"Co-immunoprecipitation, STAT5 phosphorylation assays, STAT5 DNA-binding assays, ectopic Pim-1 expression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP with functional STAT5 assays, single lab, mechanism of stabilization inferred rather than directly demonstrated\",\n      \"pmids\": [\"14764533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SOCS1/JAB associates with both JAK1 and JAK3 in cotransfection experiments, as well as with IL-2Rβ through the A region (residues 313-382). SOCS1 overexpression strongly inhibits IL-2-induced STAT5 phosphorylation and transcriptional activity, with greater effect on JAK1 than JAK3. The IL-2Rβ interaction was not essential for inhibitory action.\",\n      \"method\": \"Co-immunoprecipitation, STAT5 phosphorylation assays, transcriptional activity assays, deletion mutants\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP with functional STAT5 assays, single lab\",\n      \"pmids\": [\"11133764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SOCS1/JAB/SSI-1 (identified as TIP3) associates with Tec tyrosine kinase in 293 cells and suppresses its kinase activity, as well as down-regulating JAK2 activity. SOCS1 did not downregulate Lyn kinase activity, demonstrating substrate selectivity.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation in 293 cells, in vitro kinase assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — yeast two-hybrid plus co-IP and kinase activity assay, single lab\",\n      \"pmids\": [\"9341160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SOCS1 localizes to the microtubule organizing complex (MTOC) and co-purifies with the MTOC-associated 20S proteasome; this localization requires the SH2 domain of SOCS1. Overexpression of SOCS1 targets JAK1 to a perinuclear distribution resembling the MTOC-associated proteasome. Nocodazole (microtubule depolymerization) inhibits SOCS1 protein turnover, indicating that minus-end transport to the MTOC-associated proteasome regulates SOCS1 levels.\",\n      \"method\": \"Immunofluorescence colocalization, biochemical co-purification, SH2 domain deletion mutants, nocodazole treatment, fractionation from SOCS1-deficient cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (colocalization, co-purification, KO cells, pharmacological perturbation) in one study\",\n      \"pmids\": [\"15456882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SOCS1 expression is repressed at the level of translation initiation by the 5' untranslated region, mediated by two upstream AUGs. SOCS1 translation is cap-dependent and modulated by eIF4E-binding proteins.\",\n      \"method\": \"5'UTR deletion/mutation constructs, translation reporter assays, eIF4E-binding protein manipulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structure-function analysis with reporter assays, single lab\",\n      \"pmids\": [\"10764816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SOCS1 can suppress CD3ζ- and Syk-mediated NF-AT activation in non-lymphoid cells by interacting with Syk and with immunoreceptor tyrosine-based activation motifs (ITAMs) in CD3ζ.\",\n      \"method\": \"Cotransfection in 293T cells, NF-AT reporter assays, co-immunoprecipitation\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP plus functional NF-AT reporter assay, single lab\",\n      \"pmids\": [\"10788618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A dominant-negative SOCS1 mutant (F59D-JAB) sustained JAK/STAT activation by chelating the Elongin BC complex, thereby destabilizing wild-type JAB and CIS3 (SOCS3). The SOCS box interaction with Elongin BC stabilizes SOCS1 itself; overexpression of Elongin BC canceled F59D-JAB-induced destabilization of wild-type JAB.\",\n      \"method\": \"Transgenic mice with F59D-JAB, T cell stimulation assays, 293 cell cotransfection, protein stability assays, Elongin BC overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — transgenic mouse model plus cell-based mechanistic assays, single lab\",\n      \"pmids\": [\"11522790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"JAKs (Jak1 and Jak2) bind to TNF receptor-1 (TNFR-1) and are activated by TNF-α. SOCS1 suppresses TNF-α-induced apoptosis by inhibiting JAK activation and caspase activation downstream. In JAK-deficient cell lines, DNA fragmentation and caspase-8 activation by TNF-α are reduced, establishing that JAKs participate in TNF-α-induced apoptosis signaling.\",\n      \"method\": \"Co-immunoprecipitation (JAK-TNFR1), SOCS1 overexpression, JAK-deficient cell lines, caspase activity assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus JAK-deficient cell lines with functional caspase assays, single lab\",\n      \"pmids\": [\"15173123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS1 promotes nuclear redistribution and K63-ubiquitylation of VHL in response to DNA double-strand breaks. Loss of VHL or VHL mutations that compromise its K63-ubiquitylation attenuates the DNA-damage response, resulting in decreased homologous recombination repair.\",\n      \"method\": \"Ubiquitylation assays (K63-specific), subcellular fractionation/localization, VHL mutant analysis, DNA repair assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitylation assays with K63-specific analysis plus localization and functional DNA repair readout, single lab\",\n      \"pmids\": [\"23455319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SOCS1 mediates ubiquitylation and degradation of the GM-CSF receptor β-common (βc) signaling subunit (GMRβc), attenuating GM-CSF-induced downstream signaling.\",\n      \"method\": \"Ubiquitylation assays, protein degradation assays, signaling readouts (downstream GM-CSF pathway)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ubiquitylation and degradation assays with signaling readout, single lab\",\n      \"pmids\": [\"24086733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Bcr-Abl tyrosine phosphorylates SOCS1 mainly on Tyr155 and Tyr204, which is associated with SOCS1 binding to Bcr-Abl. This phosphorylation diminishes SOCS1 inhibitory effects on JAK and STAT5 activation. Disruption of SOCS1 tyrosine phosphorylation impaired Bcr-Abl-mediated tumorigenesis in vivo and blocked Bcr-Abl bone marrow transformation.\",\n      \"method\": \"Mass spectrometry, site-directed mutagenesis, co-immunoprecipitation, STAT5/JAK phosphorylation assays, nude mouse tumorigenesis assay, bone marrow transformation assay\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — MS identification of phosphosites, mutagenesis, co-IP, and in vivo tumorigenesis validation\",\n      \"pmids\": [\"22787435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SOCS1 Y80 in the SH2 domain is phosphorylated by SRC family kinases; phosphomimetic substitution at Y80 inhibits SOCS1-p53 interaction and abolishes p53 transcriptional activity stimulation, growth arrest, and cellular senescence. Mass spectrometry confirmed Y80 phosphorylation in cells. SRC family kinase inhibitors potentiated the SOCS1-p53 pathway. In lymphomas overexpressing SOCS1, constitutive SRC family kinase activation leads to SOCS1 Y80 phosphorylation and cytoplasmic SOCS1 localization.\",\n      \"method\": \"Mass spectrometry, site-directed mutagenesis (phosphomimetic Y80E), co-immunoprecipitation, p53 transcriptional activity assays, senescence assays, kinase library screen, IHC with phospho-specific antibody\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — MS-confirmed phosphorylation, mutagenesis, kinase library screen, co-IP, and functional senescence assays with in vivo tissue validation\",\n      \"pmids\": [\"31101761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Glucocorticoid receptor (GR) and SOCS1 form an intracellular complex; the interaction requires the SH2 domain of SOCS1 and the ligand-binding domain of GR. GC stimulation increases nuclear levels of SOCS1. SOCS1 binding to GR negatively influences transcription of GR-regulated genes FKBP5 and MKP1, as shown by IFNγ-induced SOCS1 inhibiting their expression and enhanced expression in SOCS1-deficient fibroblasts.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, SH2 domain deletion mutants, SOCS1-deficient MEFs, gene expression assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP with domain mapping and SOCS1 KO functional validation, single lab\",\n      \"pmids\": [\"18524780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOCS1 acts as a negative regulator of macrophage metabolic reprogramming during sepsis. Myeloid-specific SOCS1 deletion increases glycolysis (elevated lactic acid, hexokinase, LDHA, GLUT1 expression) in septic macrophages via the STAT3/HIF-1α/glycolysis axis. A SOCS1 KIR-blocking peptide (iKIR) increases CLP-induced mortality, confirming that SOCS1 KIR domain activity is required for this function.\",\n      \"method\": \"Myeloid-specific conditional SOCS1 knockout mice, cecal ligation and puncture model, metabolic measurements (lactate, glycolytic enzyme expression), KIR peptide inhibitor (iKIR), STAT3/HIF-1α pathway analysis, glycolysis inhibitor rescue\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO mice plus peptide inhibitor with metabolic and pathway rescue experiments\",\n      \"pmids\": [\"28679957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Threonine phosphorylation of SOCS1 by Pim-1 (induced by Pasteurella multocida Toxin) disrupts SOCS1 E3 ubiquitin ligase activity toward JAK2, preventing JAK2 from being marked for proteasomal degradation. This leads to increased JAK2 and STAT3 activity and increased anchorage-independent growth.\",\n      \"method\": \"Pim-1 kinase coexpression, SOCS1 phosphorylation analysis, JAK2 ubiquitination/degradation assays, STAT3 activity assays, anchorage-independent growth assay\",\n      \"journal\": \"Cellular microbiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — mechanistic link between Pim-1 phosphorylation and SOCS1 E3 ligase impairment demonstrated functionally, single lab\",\n      \"pmids\": [\"20633028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SOCS1 regulates IFN-dependent pathways (IFN-β production and STAT1 phosphorylation) downstream of TLR4 in human monocytes, but does not regulate early NF-κB activation or DNA binding capacity in LPS-stimulated human monocytes.\",\n      \"method\": \"Adenoviral SOCS1 overexpression in primary human monocytes, NF-κB DNA-binding assays, STAT1 phosphorylation assays, IFN-β mRNA/protein measurement, cytokine ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — adenoviral overexpression in primary human cells with pathway-specific readouts, single lab\",\n      \"pmids\": [\"19017994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SOCS1 regulates cellular senescence and ferroptosis through p53 target genes. SOCS1 reduces expression of the cystine transporter SLC7A11 and glutathione levels, sensitizing cells to ferroptosis. This effect requires SOCS1 sufficiency and correlates with its ability to regulate p53 target gene expression.\",\n      \"method\": \"Transcriptome analysis, SOCS1 overexpression/inhibition, SLC7A11 expression assays, glutathione measurement, ferroptosis assays\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional assays linking SOCS1 to ferroptosis via p53/SLC7A11/glutathione axis, single lab\",\n      \"pmids\": [\"29081404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Heterozygous germline loss-of-function mutations in SOCS1 cause haploinsufficiency resulting in enhanced STAT1, STAT3 (to a lesser degree), and STAT5/STAT6 activation in patient-derived lymphocytes in response to IFN-γ, IL-2, and IL-4. This enhanced STAT activation was reverted by JAK1/JAK2 inhibitor ruxolitinib, establishing JAK-STAT hyperactivation as the cellular mechanism of disease.\",\n      \"method\": \"Whole-exome/genome sequencing, patient-derived lymphocyte stimulation assays, STAT phosphorylation assays, JAK inhibitor (ruxolitinib) rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — natural human loss-of-function mutations validated in patient cells with pharmacological rescue, multi-family cohort\",\n      \"pmids\": [\"33087723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SOCS1 regulates CCR7 expression and T cell trafficking to peripheral tissues. In SOCS1-deficient mice, CCR7 is markedly reduced on T cells correlating with hyperactivation of STAT6. Forced SOCS1 overexpression in T cells upregulates CCR7 and enhances chemotaxis toward CCL19/CCL21. CCR6 and CXCR3 are also upregulated on SOCS1-deficient T cells.\",\n      \"method\": \"SOCS1 KO, STAT1 KO, STAT6 KO mice; stable SOCS1 overexpression/deletion in T cells; flow cytometry; chemotaxis assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mouse KO models and gain/loss-of-function in T cells with functional chemotaxis readout, single lab\",\n      \"pmids\": [\"18606672\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SOCS1 is a negative-feedback regulator of JAK-STAT and related signaling pathways that operates through multiple distinct mechanisms: (1) direct inhibition of JAK catalytic activity via its kinase inhibitory region (KIR), which binds the phosphorylated activation loop (Y1007) of JAK2 with its extended SH2 domain and pseudosubstrate-like KIR motif; (2) E3 ubiquitin ligase activity, scaffolded by its SOCS box engaging Elongin B/C and Cullin-2/5, which ubiquitinates substrates including activated JAK2, IRS1/2, GMR-βc, and VHL for proteasomal degradation; (3) tumor suppressor functions through direct SH2-domain interaction with the p53 transactivation domain and SOCS-box-mediated engagement of ATM/ATR, enabling p53 activation and senescence; (4) regulation of its own stability and activity by post-translational modifications—Pim kinases phosphorylate and stabilize SOCS1, while SRC family kinases phosphorylate Y80 in the SH2 domain to block p53 interaction and cytoplasmic sequestration, and Bcr-Abl phosphorylates Y155/Y204 to inactivate its inhibitory function; (5) translational repression via upstream AUGs in its 5'UTR; and (6) localization to the MTOC-associated 20S proteasome via its SH2 domain, linking it directly to the proteasome pathway.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SOCS1 is a cytokine-inducible negative-feedback regulator of JAK-STAT signaling that operates as both a direct kinase inhibitor and a substrate-recruiting component of an E3 ubiquitin ligase [#0, #2, #5]. Its core inhibitory mechanism couples an extended SH2 domain, which binds the phosphorylated activation-loop tyrosine (Y1007) of JAK2, to an adjacent kinase inhibitory region (KIR) that occupies the substrate-binding groove of the JAK catalytic domain to block phosphorylation [#0, #1]. Strongly induced by IFN-γ, SOCS1 thereby suppresses JAK1/JAK2 activation, STAT1 tyrosine phosphorylation, and the antiviral response [#5], and analogous inhibition extends to JAK3/IL-2Rβ-driven STAT5 signaling [#11]. In parallel, SOCS1 functions as an adaptor of a Cullin-Elongin BC E3 ligase: its SOCS box engages Elongin B/C and Cullin-2, while the SH2 domain selects substrates for K48-linked ubiquitination and proteasomal degradation, including IRS1/IRS2, the leukemic fusion TEL-JAK2, and the GM-CSF receptor βc subunit [#3, #4, #19]. Beyond cytokine signaling, SOCS1 acts as a tumor suppressor by binding the p53 transactivation domain through its SH2 domain and engaging ATM/ATR through its SOCS box to drive p53 phosphorylation, transcriptional activity, and senescence, and it also directs K63-ubiquitylation of VHL to support DNA double-strand-break repair [#7, #18]. SOCS1 abundance and activity are tightly tuned post-transcriptionally: SOCS box-Elongin BC engagement stabilizes the protein [#2, #16], translation is repressed by upstream AUGs in its 5'UTR [#14], and turnover is linked to MTOC-associated 20S proteasome localization via the SH2 domain [#13]. Pim kinases phosphorylate and stabilize SOCS1 to potentiate STAT inhibition [#9], whereas SRC-family phosphorylation of Y80 blocks the p53 interaction and drives cytoplasmic sequestration, and Bcr-Abl phosphorylation of Y155/Y204 inactivates JAK/STAT inhibition to promote transformation [#21, #20]. Heterozygous germline loss-of-function mutations in SOCS1 cause an autoimmune/inflammatory disorder of JAK-STAT hyperactivation reversible by ruxolitinib [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the molecular basis of JAK inhibition: how SOCS1 recognizes an active kinase and shuts it off.\",\n      \"evidence\": \"In vitro binding and kinase assays with site-directed mutagenesis mapping SH2/extended-SH2 and KIR contacts on JAK2 Y1007\",\n      \"pmids\": [\"10064597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibition demonstrated for JAK2; specificity across all JAK family members not fully resolved in this study\", \"No high-resolution co-structure provided at this stage\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the modular domain architecture (pre-SH2, SH2, SOCS box) required for cytokine suppression and protein stability, clarifying division of labor within SOCS1.\",\n      \"evidence\": \"Deletion mutagenesis with co-IP, reporter assays, and proteasome inhibition in the IL-6 system\",\n      \"pmids\": [\"9789053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SOCS box partner identity (Elongin BC) inferred, not yet biochemically defined here\", \"Did not resolve which JAK is the principal physiological target\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Connected SOCS1 to a physiological feedback loop, showing IFN-induced SOCS1 confers cytokine/antiviral resistance via JAK-STAT1 blockade.\",\n      \"evidence\": \"Stable overexpression with kinase, STAT1 phosphorylation/DNA-binding, and antiviral assays\",\n      \"pmids\": [\"9716595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Constitutive SOCS1 in IFN-resistant tumors observational, not causally tested\", \"Endogenous induction kinetics not dissected\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed SOCS1 is not only a kinase blocker but an E3 ligase adaptor, recruiting Cullin-2/Elongin BC to ubiquitinate and degrade phosphorylated JAK substrates.\",\n      \"evidence\": \"Ubiquitination assays, dominant-negative Cullin-2 rescue, and proteasome inhibition on TEL-JAK2\",\n      \"pmids\": [\"11278610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Demonstrated on a leukemic fusion; degradation of native full-length JAK2 generality not fully established\", \"Stoichiometry and chain linkage not characterized\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Extended the ligase mechanism to metabolic signaling, showing SOCS1 targets IRS1/IRS2 for degradation with in vivo physiological consequence.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, SOCS box mutagenesis, and adenoviral SOCS1 expression in mouse liver with glucose tolerance testing\",\n      \"pmids\": [\"12228220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adenoviral overexpression may exceed physiological levels\", \"Did not separate degradation from kinase-inhibitory contributions to glucose intolerance\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed SOCS1 in innate immune feedback, demonstrating it restrains LPS-driven NF-κB/STAT1 activation and is required for endotoxin tolerance.\",\n      \"evidence\": \"SOCS1 knockout mice, macrophage stimulation, and forced expression with NF-κB/STAT1 readouts\",\n      \"pmids\": [\"12433373\", \"12433365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target on the TLR4 pathway not defined here\", \"NF-κB regulation later found cell-type dependent\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified Pim kinases as positive regulators that phosphorylate and stabilize SOCS1, defining a kinase-controlled input to feedback strength.\",\n      \"evidence\": \"Co-IP, phosphorylation/stability assays, and Pim-1/Pim-2 double-knockout mice with STAT6 readout\",\n      \"pmids\": [\"11854514\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphosites on SOCS1 not mapped here\", \"Mechanism linking phosphorylation to stabilization inferred\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the cellular geography of SOCS1 turnover, localizing it to the MTOC-associated 20S proteasome via its SH2 domain.\",\n      \"evidence\": \"Immunofluorescence colocalization, co-purification, SH2 deletion, and nocodazole perturbation in SOCS1-deficient cells\",\n      \"pmids\": [\"15456882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional necessity of MTOC localization for substrate degradation not established\", \"Transport machinery for minus-end delivery not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Uncovered a tumor-suppressor mechanism distinct from cytokine signaling: SOCS1 directly engages p53 and ATM/ATR to drive p53 activation and senescence.\",\n      \"evidence\": \"Reciprocal co-IP, DNA-damage foci colocalization, p53 reporter assays, and loss/gain-of-function in fibroblasts\",\n      \"pmids\": [\"20005840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SOCS1 ligase activity acts on p53/ATM substrates not resolved here\", \"Link to STAT5 context-dependency incompletely mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed oncogenic kinases can inactivate SOCS1, with Bcr-Abl phosphorylating Y155/Y204 to disable JAK/STAT inhibition and enable transformation.\",\n      \"evidence\": \"Mass spectrometry, mutagenesis, co-IP, STAT5/JAK assays, and in vivo tumorigenesis/bone marrow transformation\",\n      \"pmids\": [\"22787435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how Y155/Y204 phosphorylation disrupts KIR/SH2 function not defined\", \"Contribution of degradation versus kinase inhibition to the rescued phenotype unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Expanded the ligase output to the DNA-damage response, showing SOCS1 directs K63-ubiquitylation and nuclear redistribution of VHL to support homologous recombination.\",\n      \"evidence\": \"K63-specific ubiquitylation assays, localization, VHL mutant analysis, and DNA repair readouts\",\n      \"pmids\": [\"23455319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; reciprocal validation limited\", \"How SOCS1 switches from K48-degradative to K63-signaling ubiquitination not explained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked SOCS1's KIR-dependent activity to control of macrophage metabolic reprogramming via the STAT3/HIF-1α/glycolysis axis during sepsis.\",\n      \"evidence\": \"Myeloid-specific SOCS1 knockout, CLP sepsis model, metabolic measurements, and KIR-blocking peptide (iKIR)\",\n      \"pmids\": [\"28679957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase target driving STAT3/HIF-1α not pinpointed\", \"Whether ligase activity contributes alongside KIR not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a switch governing SOCS1's tumor-suppressor arm: SRC-family phosphorylation of Y80 blocks p53 binding and drives cytoplasmic SOCS1 in lymphoma.\",\n      \"evidence\": \"Mass spectrometry, Y80E phosphomimetic mutagenesis, kinase library screen, co-IP, senescence assays, and IHC\",\n      \"pmids\": [\"31101761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Y80 phosphorylation also alters JAK inhibition not addressed\", \"Reversibility/phosphatase regulation of Y80 not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established human disease relevance: SOCS1 haploinsufficiency causes JAK-STAT hyperactivation reversible by JAK inhibition.\",\n      \"evidence\": \"Exome/genome sequencing of patients, lymphocyte STAT phosphorylation assays, and ruxolitinib rescue\",\n      \"pmids\": [\"33087723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype variability across families not fully explained\", \"Which downstream STAT dominates pathology not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SOCS1 partitions between its kinase-inhibitory, K48-degradative, and K63-signaling/p53 tumor-suppressor functions in a given cell, and what dictates substrate and ubiquitin-linkage choice, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model integrating direct inhibition versus ligase versus p53 functions\", \"Regulation of ubiquitin chain-type choice (K48 vs K63) unknown\", \"In vivo balance of these arms across tissues not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [3, 4, 18, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 11, 16]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [3, 4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13, 21]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 23, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 4, 19]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [17, 26]}\n    ],\n    \"complexes\": [\n      \"Elongin BC-Cullin-2 E3 ubiquitin ligase\",\n      \"MTOC-associated 20S proteasome\"\n    ],\n    \"partners\": [\n      \"JAK2\",\n      \"JAK1\",\n      \"TYK2\",\n      \"Elongin B/C\",\n      \"Cullin-2\",\n      \"TP53\",\n      \"Pim-1\",\n      \"VHL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}